FDA cracking down on fat-melting injections

Apr 07, 2010 By MATTHEW PERRONE , AP Business Writer

(AP) -- The Food and Drug Administration is cracking down on fat-melting injections used in spas across the U.S., saying the drugs have not been proven safe or effective.

Lipodissolve injections, a popular nonsurgical alternative to liposuction, are used to dissolve small fat deposits around the legs, arms and belly. The FDA said Wednesday the drugs have not been cleared by federal scientists, as required by law.

The agency issued warning letters to a half-dozen spas that offer the injections, citing them for making unsubstantiated claims about lipodissolve therapy.

"The claims made for your lipodissolve products are false and misleading in that they are not supported by substantial evidence or substantial clinical experience," states a letter to All About You Medspa in Madison, Ind.

Other spas cited by the FDA included: Pure Med Spa of Boca Raton, Fla., Monarch Med Spa of King of Prussia, Pa., and three others.

The Web site for Monarch Med Spa claims that, "Rather than go through the pain and discomfort associated with liposuction, patients now have the option of a series of injections with very minimal discomfort."

Calls to Monarch Med Spa were not immediately returned midday Wednesday.

FDA regulators called on the spas to stop using such claims and notify the agency within 15 working days of steps they are taking to correct the violations.

Spas that offer the injections say they are safe and effective. But safety advocates have called for proof and urge patients to think twice before paying thousands of dollars for an unproven procedure.

Some patients have complained of swelling, hard lumps and dark spots on their skin after receiving the therapy.

Lipodissolve and similar treatments use two chemicals, phosphatidylcholine, or PC, and sodium dioxycholate, or DC. Injections with the PC/DC mix aren't a treatment for obesity but a way to dissolve deposits of fat in certain areas.

Explore further: No added benefit proven for umeclidinium/vilanterol in COPD

4.3 /5 (3 votes)
add to favorites email to friend print save as pdf

Related Stories

FDA sends Procter & Gamble a warning

Sep 18, 2007

The U. S. Food and Drug Administration has warned the Procter & Gamble Co. about claims it makes for its Vicks Early Defense Foaming Hand Sanitizer.

Millennials' medspa influence

Jun 24, 2008

[B]Women ages 18-34 are empowering the medical spa trend but doing little to advocate their own safety within the facility[/B] The American Academy of Cosmetic Surgery has released its results from a consumer survey ask ...

FDA concerned about some STD medications

Mar 10, 2008

The U.S. Food and Drug Administration has warned six companies to stop marketing unapproved drugs for treating and preventing sexually transmitted diseases.

Recommended for you

No added benefit proven for umeclidinium/vilanterol in COPD

5 hours ago

The drug combination umeclidinium/vilanterol (trade name Anoro) has been approved since May 2014 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform ...

Ebola vaccine not before late 2016: GSK researcher

Oct 17, 2014

An Ebola vaccine by British pharmaceuticals giant GlaxoSmithKline may not be ready for commercial use until late 2016 and should therefore not be seen as the "primary answer" to the current outbreak, a company researcher ...

Chimerix gets FDA OK to test drug for Ebola

Oct 17, 2014

(AP)—A North Carolina drugmaker plans to test its experimental antiviral drug in patients who have Ebola, after getting authorization from regulators at the Food and Drug Administration.

Esbriet, ofev approved to treat deadly lung disease

Oct 16, 2014

(HealthDay)—Two new drugs have been approved by the U.S. Food and Drug Administration to treat progressive lung scarring from an uncertain cause, medically called idiopathic pulmonary fibrosis (IPF).

FDA weighs removing bolded warning from Chantix

Oct 14, 2014

(AP)—The Food and Drug Administration will ask a panel of experts later this week whether a bold-letter warning on the anti-smoking drug Chantix should be removed based on company-supported evidence that the drug does not ...

User comments : 0